PRA Health Sciences takes a patient-centric approach in creating all of its tools, trials, and experiences. Each of our Centers collaborates within and beyond PRA to offer the best technology and innovation for patients as we work toward global health.
To commemorate this year’s Patient Experience Week—which celebrates healthcare staff impacting patient experience and provides a focused time for organizations to celebrate accomplishments, re-energize efforts, and honor the people who impact patient experience everyday—we share the importance of a patient-centric approach.
When designing trials, we focus on patient needs to make trials available to as many people as possible. Patient-centricity means creating more access, diversity, and better solutions for patients.
PRA collaborates with partners, patients, and others within and outside the industry to ensure we offer the best options for patients. We strive to create opportunities for patients who may not otherwise have them and involve patients in an industry that works to develop treatments for them.
To commemorate this year’s Patient Experience Week—which celebrates healthcare staff impacting patient experience and provides a focused time for organizations to celebrate accomplishments, re-energize efforts, and honor the people who impact patient experience everyday—we share the importance of patient-centric approaches below.
Why Are Patient-Centric Trials Important?
Focusing on patient-centric clinical trials makes those trials more efficient, allows us to collect better data, and breaks down barriers to patient participation. With over 90% of rare diseases lacking effective treatment, the industry needs to focus on how to make trials more accessible and tailored to patients.
Researchers should incorporate patient feedback, which they can do with this survey. The survey helps researchers better collaborate with patients and consider what they need to have an improved trial experience. A better experience leads to better data when patients feel comfortable participating in clinical trials. The survey offers researchers a starting point, so they know what changes to make to their clinical trial process.
Patient-centric trials help mitigate risks and anticipate trial issues before they become a problem. They allow researchers and experts to get the full scope of a disease as it affects patients. They also increase diversity in trials by understanding broader patient needs, boosting enrollment, reducing dropout rates, and allowing more accessibility for patients.Learn more about tools we’ve developed for a patient-centric approach to clinical trials
Technology Helps Us Meet Patient Needs
Accessibility is one of the biggest barriers for patients when it comes to participating in clinical trials and getting the care they need. Around 70% of people live over two hours from a trial site. This lack of accessibility leads to other problems, like a lack of diversity and representation in trials, especially from low-income communities.
Technology helps us reach more communities by reducing the need for travel and other expenses that would otherwise bar patients from getting to a clinical trial. PRA is making use of the new technologies available to our industry. We have apps, like our Mobile Health Platform, together with wearables, and digital therapeutics that make it easier for experts to communicate with patients and ensure an efficient and accurate clinical trial.
Remote patient monitoring helps patients stick to clinical trial regulations, adhere to medications, and remember other parts of their health routines. This technology makes for low effort on the patient’s part. In terms of clinical trials, that means fewer people drop out and researchers receive more accurate and diverse results.
While we’re designing Decentralized Clinical Trials (DCTs), other tools continue evolving. One-touch consent lets patients give their consent to participate without an in-person visit. Digital therapeutics, like apps and Artificial Intelligence (AI), make treatment more available to patients by adhering to their specific needs and promoting communication with healthcare professionals. Each of these tools factor into creating remote clinical trials that allow patients to trust the experts they work with, participate with ease, and better understand the process as they go through it.Learn more about the current technologies being used in decentralized clinical trials
Designing Trials for Patient-Centricity
Experts at PRA work with patient advocacy groups to meet patient needs, especially in the Center for Rare Diseases. With so many rare diseases, we must listen to individual patient needs if we want to know how to best help people affected by them.
According to Laura Iliescu from the Center for Rare Diseases, part of patient advocacy is changing the system to benefit patients. We do that by interacting and combining the knowledge and efforts of people who work to better life for rare disease patients.
The Center also works with patient advocacy groups that have or know someone who has a rare disease and work to uplift those voices. When we work with them, we hear patient needs and get input that gives us a more complete picture of patient perspectives and priorities.
Putting patients first helps us create more cost-effective solutions that offer greater benefits to patients. Collaboration with patient advocacy groups helps with recruiting, support, funding, patient registration, and patient history. Throughout a clinical trial or study, they have a part in increasing awareness and retention, as well as promoting education about rare diseases. Ultimately, this relationship allows PRA to continue doing more clinical trials that provide more treatments to rare disease patients.
By prioritizing patient voices and understanding patient needs, PRA facilitates successful clinical trials and innovates in ways that benefit patients first. When we create patient-centric solutions, we also improve the healthcare and pharmaceutical industries, allowing us to continue collaborating with people and organizations that prioritize patients.
RARE DISEASES NEWSLETTER Volume 8, January 2018
This quarterly publication will keep you up to date on PRA’s Rare Disease Team focus, achievements, and new initiatives.
Three Necessary Steps When Designing your New World Protocol
This article explores the design of a protocol that includes decentralized components. After a clinical-trial protocol has been developed, adding…
RARE DISEASES NEWSLETTER Volume 17, July 2020
Welcome to the seventeenth edition of the rare disease newsletter. A few months has changed the world of clinical research into a very different…